Euphoria

History {{anchor|History of the term}}

The word "euphoria" is derived from the Ancient Greek terms εὐφορία: εὖ eu meaning "well" and φέρω pherō meaning "to bear". It is semantically opposite to dysphoria.

A 1706 English dictionary defines euphoria as "the well bearing of the Operation of a Medicine, i.e., when the patient finds himself eas'd or reliev'd by it".

During the 1860s, the English physician Thomas Laycock described euphoria as the feeling of bodily well-being and hopefulness; he noted its misplaced presentation in the final stage of some terminal illnesses and attributed such euphoria to neurological dysfunction.

• Sigmund Freud's 1884 monograph Über Coca described (his own) consumption of cocaine producing "the normal euphoria of a healthy person", while about 1890 the German neuropsychiatrist Carl Wernicke lectured about the "abnormal euphoria" in patients with mania.

A 1903 article in The Boston Daily Globe refers to euphoria as "pleasant excitement" and "the sense of ease and well-being". In 1920 Popular Science magazine described euphoria as "a high sounding name" meaning "feeling fit": normally making life worth living, motivating drug use, and ill formed in certain mental illnesses. Robert S. Woodworth's 1921 textbook Psychology: A study of mental life, describes euphoria as an organic state which is the opposite of fatigue, and "means about the same as feeling good."

In 1940, The Journal of Psychology defined euphoria as a "state of general well being ... and pleasantly toned feeling." A decade later, finding ordinary feelings of well being difficult to evaluate, American addiction researcher Harris Isbell redefined euphoria as behavioral changes and objective signs typical of morphine. However, in 1957 British pharmacologist D. A. Cahal did not regard opioid euphoria as medically undesirable but an effect which "enhance[s] the value of a major analgesic." The 1977 edition of A Concise Encyclopaedia of Psychiatry called euphoria "a mood of contentment and well-being," with pathologic associations when used in a psychiatric context. As a sign of cerebral disease, it was described as bland and out of context, representing an inability to experience negative emotion.

In the 21st century, euphoria is generally defined as a state of great happiness, well-being and excitement, which may be normal, or abnormal and inappropriate when associated with psychoactive drugs, manic states, or brain disease or injury.

Neuropsychology {{anchor|Neural substrates}}

Main article: Reward system#Pleasure centers

Hedonic hotspots are functionally interrelated neural substrates/structures that (intrinsically or extrinsically) generate the feelings of pleasure. Activation of one hedonic hotspot involves the stimulation of the others. Inhibition of one hedonic hotspot blunts the activation the other ones. Therefore, the simultaneous activation of every hedonic hotspot within the reward system is probably necessary for generating the sensation of euphoria.

Types

Many different types of stimuli can induce euphoria, including psychoactive drugs, natural rewards, and social activities. Affective disorders such as unipolar mania or bipolar disorder can involve euphoria as a symptom.

Exercise-induced

Music-induced {{Anchor|Music euphoria}}

Euphoria can occur as a result of dancing to music, music-making, and listening to emotionally arousing music. Neuroimaging studies have demonstrated that the reward system plays a central role in mediating music-induced pleasure. Pleasurable emotionally arousing music strongly increases dopamine neurotransmission in the dopaminergic pathways that project to the striatum (i.e., the mesolimbic pathway and nigrostriatal pathway). Approximately 5% of the population experiences a phenomenon termed "musical anhedonia", in which individuals do not experience pleasure from listening to emotionally arousing music despite having the ability to perceive the intended emotion that is conveyed in passages of music.

A clinical study from January 2019 that assessed the effect of a dopamine precursor (levodopa), dopamine antagonist (risperidone), and a placebo on reward responses to music – including the degree of pleasure experienced during musical chills, as measured by changes in electrodermal activity as well as subjective ratings – found that the manipulation of dopamine neurotransmission bidirectionally regulates pleasure cognition (specifically, the hedonic impact of music) in human subjects. This research suggests that increased dopamine neurotransmission acts as a sine qua non condition for pleasurable hedonic reactions to music in humans.

Sex-induced

The various stages of copulation may also be described as inducing euphoria in some people. Various analysts have described either the entire sexual act, the moments leading to orgasm, or the orgasm itself as the pinnacle of human pleasure or euphoria.

Drug-induced{{anchor|Euphoriant|Euphoriants}}

A euphoriant is a type of psychoactive drug which tends to induce euphoria. Most euphoriants are addictive drugs due to their reinforcing properties and ability to activate the brain's reward system.

Stimulants

Dopaminergic stimulants like amphetamine, methamphetamine, cocaine, MDMA, and methylphenidate are euphoriants. Nicotine is a parasympathetic stimulant that acts as a mild euphoriant in some people. Xanthines such as caffeine and theobromine may also be considered mild euphoriants by some.

Chewing areca nut (seeds from the Areca catechu palm) with slaked lime (calcium hydroxide) – a common practice in South- and Southeast Asia – produces stimulant effects and euphoria. The major psychoactive ingredients – arecoline (a muscarinic receptor partial agonist) and arecaidine (a GABA reuptake inhibitor) – are responsible for the euphoric effect.

Depressants

Certain depressants can produce euphoria; some of those drugs in this class include alcohol in moderate doses, γ-hydroxybutyric acid (GHB), and ketamine.

Some barbiturates and benzodiazepines may cause euphoria. Euphoriant effects are determined by the drug's speed of onset, increasing dose, and with intravenous administration. Barbiturates more likely to cause euphoria include amobarbital, secobarbital and pentobarbital. Benzodiazepines more likely to cause euphoria are flunitrazepam, alprazolam and clonazepam. Benzodiazepines also tend to enhance opioid-induced euphoria.

Pregabalin induces dose-dependent euphoria. Occurring in a small percentage of individuals at recommended doses, euphoria is increasingly frequent at supratherapeutic doses (or with intravenous- or nasal administration). At doses five times the maximum recommended, intense euphoria is reported. Another GABA analogue, gabapentin, may induce euphoria. Characterized as opioid-like but less intense, it may occur at supratherapeutic doses, or in combination with other drugs, such as opioids or alcohol. Ethosuximide and perampanel can also produce euphoria at therapeutic doses.

Opioids

μ-Opioid receptor agonists are a set of euphoriants that include drugs such as heroin, morphine, codeine, oxycodone, and fentanyl. By contrast, κ-opioid receptor agonists, like the endogenous neuropeptide dynorphin, are known to cause dysphoria, a mood state opposite to euphoria that involves feelings of profound discontent.

Cannabinoids

Cannabinoid receptor 1 agonists are a group of euphoriants that includes certain plant-based cannabinoids (e.g., THC from the cannabis plant), endogenous cannabinoids (e.g., anandamide), and synthetic cannabinoids.

Inhalants

Certain gases, like nitrous oxide (N2O, aka "laughing gas"), can induce euphoria when inhaled.

Psychedelics

Traditional psychedelic drugs, such as LSD and psilocybin are capable of inducing euphoria despite lacking addictive qualities. The Global Drug Survey has revealed that out of 22,000 participant reports, MDMA, LSD, and psilocybin mushrooms were ranked most positively on the Net Pleasure Index of all recreational drugs included in the study.

Glucocorticoids

Acute exogenous glucocorticoid administration is known to produce euphoria, but this effect is not observed with long-term exposure.

List of euphoriants by mechanism of action

The following is a full list of euphoriant or rewarding/reinforcing drugs:

• GABAA receptor (e.g., alcohol, benzodiazepines, Z-drugs, barbiturates, ) and agonists (e.g., muscimol, gaboxadol)
• Nicotinic acetylcholine receptor agonists (e.g., nicotine)
• Classical dopamine reuptake inhibitors (e.g., cocaine, methylphenidate) and dopamine releasing agents (e.g., amphetamine, methamphetamine) (psychostimulants)
• μ-Opioid receptor agonists (opioids) (e.g., morphine, heroin, fentanyl, hydrocodone, oxycodone)
• Cannabinoid CB1 receptor agonists (cannabinoids) (e.g., , nabilone)
• NMDA receptor antagonists (dissociatives) (e.g., ketamine, phencyclidine, nitrous oxide, dextromethorphan)
• Gabapentinoids (α2δ ligands) (e.g., gabapentin, pregabalin, phenibut)
• γ-Hydroxybutyrate (GHB) and analogues (GHB and GABAB receptor agonists) (e.g., , , )
• AMPA receptor antagonists (e.g., perampanel)
• Serotonin releasing agents (entactogens) (e.g., MDMA, MBDB, MDAI, MEAI)
• Serotonergic psychedelics (non-selective serotonin receptor agonists) (e.g., , psilocybin, mescaline, ) (mixed/variable and non-addictive)
• Glucocorticoid receptor agonists (glucocorticoids or corticosteroids) (e.g., hydrocortisone, dexamethasone)

Fasting–induced

Fasting has been associated with improved mood, well-being, and sometimes euphoria. Various mechanisms have been proposed and possible applications in treating depression considered.

Neuropsychiatric

Mania

Euphoria is also strongly associated with both hypomania and mania, mental states characterized by a pathological heightening of mood, which may be either euphoric or irritable, in addition to other symptoms, such as pressured speech, flight of ideas, and grandiosity.

Although hypomania and mania are syndromes with multiple etiologies (that is, ones that may arise from any number of conditions), they are most commonly seen in bipolar disorder, a psychiatric illness characterized by alternating periods of mania and depression.

Epilepsy

Euphoria may occur during auras of seizures typically originating in the temporal lobe, but affecting the anterior insular cortex. This euphoria is symptomatic of a rare syndrome called ecstatic seizures, often also involving mystical experiences. Euphoria (or more commonly dysphoria) may also occur in periods between epileptic seizures. This condition, interictal dysphoric disorder, is considered an atypical affective disorder. Persons who experience feelings of depression or anxiety between or before seizures occasionally experience euphoria afterwards.

Migraine

Some persons experience euphoria in the prodrome – hours to days before the onset – of a migraine headache. Similarly, a euphoric state occurs in some persons following the migraine episode.

Multiple sclerosis

Euphoria sometimes occurs in persons with multiple sclerosis as the illness progresses. This euphoria is part of a syndrome originally called euphoria sclerotica, which typically includes disinhibition and other symptoms of cognitive and behavioral dysfunction.

Gender euphoria

Gender euphoria is satisfaction or enjoyment felt by a person due to consistency between their gender identity and gendered features associated with a gender different to the sex they were assigned at birth. It is considered to be the positive counterpart of gender dysphoria. Related euphorias have also been recorded in studies of alignments between sexual identity and social recognition such as support in schools for lesbian and gay people, and experiences of intersex variation and their diagnoses such as receiving a diagnosis of congenital adrenal hyperplasia which explained physical differences for example.

References

References

1. (2015). "The Neuropsychiatric Complications of Stimulant Abuse". Academic Press.
2. (2011). "The SEEKING mind: primal neuro-affective substrates for appetitive incentive states and their pathological dynamics in addictions and depression". Neuroscience and Biobehavioral Reviews.
3. "Key DSM-IV Mental Status Exam Phrases". Gateway Psychiatric Services.
4. (July 2012). "The human sexual response cycle: brain imaging evidence linking sex to other pleasures". Prog. Neurobiol..
5. (March 2012). "Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms". Journal of Psychoactive Drugs.
6. (2013). "Intimacies: Love and Sex Across Cultures". Columbia University Press.
7. (2010). "Addiction Medicine: Science and Practice". Springer Science & Business Media.
8. (1940). "A Greek-English Lexicon". Clarendon Press.
9. "Online Etymology Dictionary".
10. (1706). "The new world of words: or, Universal English dictionary.". Printed for J. Phillips.
11. (March 2024). "Über Coca". U.S. Government Printing Office.
12. (2015). "An Outline of Psychiatry in Clinical Lectures: The Lectures of Carl Wernicke". Springer.
13. (1903). "Paris Doctors Say That Scorching is Like Effects of Drugs". Paris Herald.
14. (December 1920). "Have You Euphoria?". Popular Science.
15. (1921). "Psychology, a study of mental life". Henry Holt and Company.
16. (1940). "The Relation of the Euphoric Attitude to the Quality of Sleep". The Journal of Psychology.
17. (1952). "Analgesic activity and toxic effects of acetylmethadol isomers in man". National Institute on Drug Abuse.
18. (1957). "Analgesic activity of dipipanone hydrochloride in student volunteers". British Journal of Pharmacology and Chemotherapy.
19. (1977). "A Concise Encyclopaedia of Psychiatry". Springer Science & Business Media.
20. (2009). "definition of euphoria in English".
21. (May 2015). "Pleasure systems in the brain". Neuron.
22. (24 October 2017). "Opioid and orexin hedonic hotspots in rat orbitofrontal cortex and insula.". Proceedings of the National Academy of Sciences of the United States of America.
23. Kringelbach ML, Berridge KC. (2012). "The Joyful Mind". Scientific American.
24. (2015). "Neuronal reward and decision signals: from theories to data". Physiological Reviews.
25. (2011). "Anatomically distinct dopamine release during anticipation and experience of peak emotion to music". Nat. Neurosci..
26. (March 2015). "Music and the nucleus accumbens". Surg Radiol Anat.
27. (March 2015). "Musical pleasure and reward: mechanisms and dysfunction". Ann. N. Y. Acad. Sci..
28. (January 2019). "Dopamine modulates the reward experiences elicited by music". Proceedings of the National Academy of Sciences of the United States of America.
29. (1977). "Evidence against involvement of endorphins in sexual arousal and orgasm in man". Archives of General Psychiatry.
30. "Methamphetamine {{!}} InfoFacts {{!}} The National Institute on Drug Abuse (NIDA)".
31. "Merrian-Webster definition".
32. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
33. (2016). "Neuropathology of Drug Addictions and Substance Misuse Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions". Academic Press.
34. (June 2014). "A review of the systemic adverse effects of areca nut or betel nut". Indian Journal of Medical and Paediatric Oncology.
35. (August 2012). "Association of Betel Nut with Carcinogenesis: Revisit with a Clinical Perspective". PLOS ONE.
36. (2013). "Veterinary Pharmacology and Therapeutics". John Wiley & Sons.
37. (November 2016). "The pharmacology, toxicology and potential applications of arecoline: a review". Pharmaceutical Biology.
38. (April 2015). "Areca catechu L. (Arecaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology". Journal of Ethnopharmacology.
39. (2012). "Manual of Drug and Alcohol Abuse: Guidelines for Teaching in Medical and Health Institutions". Springer Science & Business Media.
40. Aronson, J. K.. (2009). "Meyler's Side Effects of Herbal Medicines". Elsevier.
41. (2008). "Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol". J. Neurosci..
42. (2001). "Alcohol-induced euphoria: exclusion of serotonin". Alcohol and Alcoholism.
43. (2015). "GHB Pharmacology and Toxicology: Acute Intoxication, Concentrations in Blood and Urine in Forensic Cases and Treatment of the Withdrawal Syndrome". Current Neuropharmacology.
44. (2016). "Clinical Textbook of Addictive Disorders, Fourth Edition". Guilford Publications.
45. (2014). "Pharmacology: A Patient-Centered Nursing Process Approach". Elsevier Health Sciences.
46. (2014). "Concepts of Chemical Dependency". Cengage Learning.
47. (2013). "Determinants of Substance Abuse: Biological, Psychological, and Environmental Factors". Springer Science & Business Media.
48. (2012). "Psychotropic Agents: Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs". Springer Science & Business Media.
49. (2013). "Addictions: A Comprehensive Guidebook". OUP USA.
50. (2011). "Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook". Lippincott Williams & Wilkins.
51. (2016). "Controlled Substance Management in Chronic Pain: A Balanced Approach". Springer.
52. "Lyrica". Drugs.com.
53. (January 2016). "Abuse Potential of Pregabalin: A Systematic Review". CNS Drugs.
54. (2016). "Neuropathology of Drug Addictions and Substance Misuse Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions". Academic Press.
55. (2016). "Gabapentin misuse, abuse, and diversion: A systematic review". Addiction.
56. (July 2017). "Ethosuximide". Australian Medicines Handbook Pty Ltd.
57. (July 2017). "Perampanel". Australian Medicines Handbook Pty Ltd.
58. (December 2017). "When adverse effects are seen as desirable: Abuse potential of the newer generation antiepileptic drugs". Epilepsy Behav.
59. (2016). "Nitrous Oxide, From the Operating Room to the Emergency Department". Current Emergency and Hospital Medicine Reports.
60. "Drug Pleasure Ratings | Global Drug Survey".
61. (October 2019). "The Neuroscience of Drug Reward and Addiction". Physiol Rev.
62. (July 2024). "The influence of drug class on reward in substance use disorders". Pharmacol Biochem Behav.
63. (September 2007). "Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade". Addict Biol.
64. (2022). "GABAA receptor subtypes and benzodiazepine use, misuse, and abuse". Front Psychiatry.
65. (2006). "GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic".
66. (16 January 2009). "Poster Session I (PI 1-89): PI-44: A single-dose randomized, double-blind, crossover abuse liability study to evaluate the subjective and objective effects of gaboxadol and zolpidem in recreational drug users". Clinical Pharmacology & Therapeutics.
67. (February 2002). "The subjective effects of nicotine: methodological issues, a review of experimental studies, and recommendations for future research". Nicotine Tob Res.
68. (December 2014). "Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaine". Neuropharmacology.
69. (June 2013). "Amphetamine, past and present--a pharmacological and clinical perspective". J Psychopharmacol.
70. (1994). "Neurobiological Models for Evaluating Mechanisms Underlying Cocaine Addiction (NIDA Research Monograph 145)". U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse.
71. (July 2018). "Opioid system and human emotions". Br J Pharmacol.
72. (2021). "Prospects for the Use of Cannabinoids in Psychiatric Disorders". Front Psychiatry.
73. (July 1999). "The effects of cannabinoids on the brain". Prog Neurobiol.
74. (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Test Anal.
75. (December 2022). "Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics". Prog Neuropsychopharmacol Biol Psychiatry.
76. (December 2020). "Current Evidence on Abuse and Misuse of Gabapentinoids". Drug Saf.
77. (June 2024). "Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal". J Clin Pharmacol.
78. (January 2021). "γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology". AAPS J.
79. (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol.
80. (September 2024). "Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study". Drug Test Anal.
81. (2022). "Behavioral Pharmacology of Drug Abuse: Current Status".
82. (2018). "Behavioral Neurobiology of Psychedelic Drugs".
83. (January 2017). "The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens". J Psychopharmacol.
84. (February 2000). "Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management". Drug Saf.
85. (December 1999). "The psychiatric side effects of corticosteroids". Ann Allergy Asthma Immunol.
86. (2013). "Fasting in mood disorders: neurobiology and effectiveness. A review of the literature". Psychiatry Research.
87. (2013). "Diagnostic and Statistical Manual of Mental Disorders (DSM-5)". American Psychiatric Association.
88. (June 2014). "Beyond a single index of mania symptoms: structure and validity of subdimensions". J. Affect. Disord..
89. (2007). "Behavioral Aspects of Epilepsy: Principles and Practice". Demos Medical Publishing.
90. (2011). "The Neuropsychiatry of Epilepsy". Cambridge University Press.
91. (January 2016). "Ecstatic Epileptic Seizures: A Glimpse into the Multiple Roles of the Insula". Frontiers in Behavioral Neuroscience.
92. (September 2014). "Predictions, perception, and a sense of self". Neurology.
93. (May 2008). "Spirituality and religion in epilepsy". Epilepsy & Behavior.
94. (2011). "The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill". American Psychiatric Publishing.
95. (2010). "Neuropsychiatric Disorders". Springer Science & Business Media.
96. (2013). "Seizures and Epilepsy". Oxford University Press.
97. (2016). "Migraine". Oxford University Press.
98. (2015). "Headache and Migraine Biology and Management". Academic Press.
99. (2013). "Family Medicine: Principles and Practice". Springer Science & Business Media.
100. (January 2009). "Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment". Ther. Adv. Neurol. Disord..
101. (2012). "Neuropsychiatric Dysfunction in Multiple Sclerosis". Springer Science & Business Media.
102. (2018-12-02). "In Favor of Covering Ethically Important Cosmetic Surgeries: Facial Feminization Surgery for Transgender People". The American Journal of Bioethics.
103. Jones, Tiffany. (2023). "Euphorias in gender, sex and sexuality variations: positive experiences".